Claritas to acquire exclusive rights to develop and commercialize R-107
Category: #health  By Pankaj Singh  Date: 2021-04-15
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Claritas to acquire exclusive rights to develop and commercialize R-107

Leading biotech firm, Claritas Pharmaceuticals Inc. has reportedly signed a binding Letter of Intent (LOI) with Salzman Group, a multinational company that specializes in drug development.

As per the agreement, Claritas will receive an exclusive, worldwide license to develop as well as commercialize the R-107, a nitric oxide prodrug that is used for treating pulmonary arterial hypertension (PAH).

Pulmonary arterial hypertension is basically a lethal condition that occurs due to high blood pressure in the lungs. If market speculations are right, the global PAH treatment market is likely to reach a valuation of USD 9.8 billion by the year 2027.

Reportedly, R-107 is the only agent that can demonstrate a durable reversal of the established disease within an authenticated animal model of PAH. It is basically a liquid compound with nitric oxide-releasing characteristics.

According to the President and CEO of Claritas, Robert Farrell, the deployment of R-107 would help in transforming the impractical and expensive challenges while administering inhalation, nitric oxide therapies into practical treatment methods.

Claritas had previously acquired a license from the Salzman Group for the R-107 to offer support in the treatment of COVID-19 as well as other viral infections.

The team has been focusing on developing the R-107 to treat and prevent coronavirus, influenza, and the common cold, considering the supposed demonstration of nitric oxide as a potent antiviral therapy.

It has also been reported that Claritas is looking forward to completing the Phase 1 clinical study of R-107 in 2021 and conclude its pilot Phase 2 clinical study for hospitalized patients by the year 2022.

The company’s development strategy for R-107 in PAH treatment is reportedly designed to accelerate the monetization efforts of this asset. Sources reveal that the deal is likely to be closed in May 2021, although it would be subject to regulatory approvals such as consent from the TSX Venture Exchange.

Source Credits –

https://www.globenewswire.com/news-release/2021/04/14/2210281/0/en/Claritas-Announces-Letter-of-Intent-to-Acquire-Exclusive-Worldwide-Rights-to-Develop-R-107-for-PAH.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

By Pankaj Singh

Well-known medical practice management organization, Medical Group Management Association (MGMA) has reportedly joined forces with WhiteSpace Health to release a new medical group analytics tool, MGMA DataDiscovery. Th...

Santex acquires U.S. online retailer Parentgiving for market expansion

Santex acquires U.S. online retailer Parentgiving for market expansion

By Pankaj Singh

Italy-based personal care and incontinence product manufacturer Santex SPA has reportedly acquired Parentgiving Inc., America’s top-rated e-commerce retailer of geriatric care products.

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...